Allogene Therapeutics, Inc.·4

Mar 5, 4:11 PM ET

Beneski Benjamin Machinas 4

4 · Allogene Therapeutics, Inc. · Filed Mar 5, 2025

Insider Transaction Report

Form 4
Period: 2025-03-01
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Transactions
  • Award

    Common Stock

    2025-03-01+31,755223,995 total
  • Award

    Stock Option (Right to buy)

    2025-03-01+112,339112,339 total
    Exercise: $1.80Exp: 2035-03-01Common Stock (112,339 underlying)
Footnotes (1)
  • [F1]25% of the shares subject to the stock option shall vest on March 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    wk-form4_1741209067.xmlPrimary

    FORM 4